Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L Heytens

Showing results (41-50 of 49) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 49 results.
Human Molecular Genetics|July 1, 1993
Genetic mapping of the beta 1- and gamma-subunits of the human skeletal muscle L-type voltage-dependent calcium channel on chromosome 17q and exclusion as candidate genes for malignant hyperthermia susceptibilityD E Iles, B Segers, R C Sengers, et al.
Human Molecular Genetics|June 1, 1997
A genome wide search for susceptibility loci in three European malignant hyperthermia pedigreesR L Robinson, N Monnier, W Wolz, et al.
Journal of Neurology|February 22, 2019
The histopathological spectrum of malignant hyperthermia and rhabdomyolysis due to RYR1 mutationsG J Knuiman, B Küsters, L Eshuis, et al.
American Journal of Human Genetics|April 29, 1998
Identification of novel mutations in the ryanodine-receptor gene (RYR1) in malignant hyperthermia: genotype-phenotype correlationB M Manning, K A Quane, H Ording, et al.
European Journal of Human Genetics : EJHG|April 18, 2003
Recent advances in the diagnosis of malignant hyperthermia susceptibility: how confident can we be of genetic testing?R L Robinson, M J Anetseder, V Brancadoro, et al.
Trials|December 30, 2020
Correction to: A randomized, open-label, adaptive, proof-of-concept clinical trial of modulation of host thromboinflammatory response in patients with COVID-19: the DAWn-Antico studyT Vanassche, M M Engelen, Q Van Thillo, et al.
Trials|December 10, 2020
A randomized, open-label, adaptive, proof-of-concept clinical trial of modulation of host thromboinflammatory response in patients with COVID-19: the DAWn-Antico studyT Vanassche, M M Engelen, Q Van Thillo, et al.
European Journal of Anaesthesiology|July 30, 2003
Multicentre evaluation of in vitro contracture testing with bolus administration of 4-chloro-m-cresol for diagnosis of malignant hyperthermia susceptibilityF Wappler, M Anetseder, C P Baur, et al.
Acta Anaesthesiologica Scandinavica|October 6, 1997
In vitro contracture test for diagnosis of malignant hyperthermia following the protocol of the European MH Group: results of testing patients surviving fulminant MH and unrelated low-risk subjects. The European Malignant Hyperthermia GroupH Ording, V Brancadoro, S Cozzolino, et al.
Pageof 5

Showing results (41-50 of 49) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 49 results.
Human Molecular Genetics|July 1, 1993
Genetic mapping of the beta 1- and gamma-subunits of the human skeletal muscle L-type voltage-dependent calcium channel on chromosome 17q and exclusion as candidate genes for malignant hyperthermia susceptibilityD E Iles, B Segers, R C Sengers, et al.
Human Molecular Genetics|June 1, 1997
A genome wide search for susceptibility loci in three European malignant hyperthermia pedigreesR L Robinson, N Monnier, W Wolz, et al.
Journal of Neurology|February 22, 2019
The histopathological spectrum of malignant hyperthermia and rhabdomyolysis due to RYR1 mutationsG J Knuiman, B Küsters, L Eshuis, et al.
American Journal of Human Genetics|April 29, 1998
Identification of novel mutations in the ryanodine-receptor gene (RYR1) in malignant hyperthermia: genotype-phenotype correlationB M Manning, K A Quane, H Ording, et al.
European Journal of Human Genetics : EJHG|April 18, 2003
Recent advances in the diagnosis of malignant hyperthermia susceptibility: how confident can we be of genetic testing?R L Robinson, M J Anetseder, V Brancadoro, et al.
Trials|December 30, 2020
Correction to: A randomized, open-label, adaptive, proof-of-concept clinical trial of modulation of host thromboinflammatory response in patients with COVID-19: the DAWn-Antico studyT Vanassche, M M Engelen, Q Van Thillo, et al.
Trials|December 10, 2020
A randomized, open-label, adaptive, proof-of-concept clinical trial of modulation of host thromboinflammatory response in patients with COVID-19: the DAWn-Antico studyT Vanassche, M M Engelen, Q Van Thillo, et al.
European Journal of Anaesthesiology|July 30, 2003
Multicentre evaluation of in vitro contracture testing with bolus administration of 4-chloro-m-cresol for diagnosis of malignant hyperthermia susceptibilityF Wappler, M Anetseder, C P Baur, et al.
Acta Anaesthesiologica Scandinavica|October 6, 1997
In vitro contracture test for diagnosis of malignant hyperthermia following the protocol of the European MH Group: results of testing patients surviving fulminant MH and unrelated low-risk subjects. The European Malignant Hyperthermia GroupH Ording, V Brancadoro, S Cozzolino, et al.
Pageof 5